In “modified monovision”, which can be achieved with a new IOL, one eye predominantly manages distance vision and the other near vision—as with standard monovision—but the extended depth of field provides a degree of intermediate vision that is independent of spectacles.
According to the company, the NDA submission for Nyxol eye drops in first indication is on track for late 2022.
Haiyan Gong, MD, PhD, professor of ophthalmology and anatomy and neurobiology at Boston University School of Medicine, has received $200,000 through a Standard Award in National Glaucoma Research from the BrightFocus Foundation.
Automated quantitative fluid analyses are enabling personalised treatments, better patient outcomes
A research team led by the Department of Ophthalmology, School of Clinical Medicine, LKS Faculty of Medicine of The University of Hong Kong, with collaborators from the Faculty of Medicine of The Chinese University of Hong Kong and local and international partners, have developed a new technology ROTA to unveil the optical texture and trajectories of the axonal fiber bundles on the retina.
Zeiss parlays technology into standardization for ophthalmologists and their patients
Taking place from 16–20 September 2022, and following the success of last year’s congress, the 40th ESCRS will again be a face-to-face event but supported by a virtual conferencing platform that will allow the sessions to also be streamed.
Oral APX3330 was found to demonstrate favorable safety and tolerability profile in interim masked safety results, consistent with 11 prior trials of APX3330.
Scientist have proposed several methods for converting stem cells into RPE, but there is still a gap in our knowledge of how cells respond to these stimuli over time.
Spanish investigators from the Ophthalmology Service, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, led by first author Fernando Ly-Yang, MD, reported the case of a 42-year-old man with monkeypox.
Data highlights need for educational materials and training resources in DMO and DR.
Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.
The research, presented at the 22nd EURETINA World Congress, outlined that patients with RP experience greater levels of stress and anxiety than individuals in the general population and that the level of stress can be measured easily and non-invasively in hair.
During the 22nd European Society of Retina Specialists Congress in Hamburg, Germany., investigators noted that Yusar and colleagues from the Vitreoretinal Services, Centre for Sight, Delhi, India.
12-week interim results of BEHOLD, a proof-of-concept Phase 2a study investigating the candidate UBX1325, provides a positive outlook for a novel senolytic approach for previously-treated patients with diabetic macular oedema.
Oral ZPX3330 found to demonstrate favorable safety and tolerability profile in interim masked safety results, consistent with 11 Prior Trials of APX3330.
According to the company, the Phase 3 pivotal trials met pre-specified primary efficacy endpoints for both doses of iDose TR., supported an anticipated upcoming NDA submission.
Elisabeth J. Cohen, MD, has been appointed vice chair for academic affairs, enhancing the department’s commitment to research and advancing its reputation for excellence in studying and treating diseases of the eye.
Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.
The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.
Timing of type 2 diabetes or hypertension diagnosis may impact the risk of primary open-angle glaucoma.
According to the National Institutes of Health, the therapy was derived from the patient’s blood by converting blood cells to iPS cells which were then programmed to become retinal pigment epithelial cells, which were surgically implanted as a patch of tissue.
Craig Morgan, MD, and Eye Consultants of Huntington, West Virginia, paid $907,074.64 to resolve allegations that they submitted false claims to Medicare and Medicaid, the U.S. Attorney’s Office for the Southern District of West Virginia reported.
Symptoms of acute optic neuritis resulting from the disease can resolve in treated rapidly.
The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.
According to a presentation by Oculis at EURETINA, the dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.
If approved, TP-03 may offer treatment for millions of patients with Demodex blepharitis. TP-03 is now also being studied for the treatment of Meibomian Gland Disease in patients with Demodex mites.
Eyecare specialists benefit from being able to monitor their patients long term for optimised and personalised treatment regimens, as well as having access to a more efficient workflow and one which enables them to see more patients.
According to Dr Gregor S. Reiter, the results from the multicentre Phase 3 clinical trial demonstrated that fluid volumes in patients with nAMD can be precisely identified, localised and measured in real-time using artificial intelligence.
Automated quantitative fluid analyses are enabling personalised treatments, better patient outcomes.
